GB2551979A - Cleavable polymer drug conjugates - Google Patents

Cleavable polymer drug conjugates Download PDF

Info

Publication number
GB2551979A
GB2551979A GB1611405.0A GB201611405A GB2551979A GB 2551979 A GB2551979 A GB 2551979A GB 201611405 A GB201611405 A GB 201611405A GB 2551979 A GB2551979 A GB 2551979A
Authority
GB
United Kingdom
Prior art keywords
polymer
drug conjugate
formula
conjugate according
bromoisobutyrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1611405.0A
Other languages
English (en)
Other versions
GB201611405D0 (en
Inventor
Sanyal Amitav
Kaga Sadik
Gok Ozgul
Karacivi Merve
Arslan Mehmet
Sumer Bolu Burcu
Sanyal Rana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rs Arastirma Egitim Danismanlik Llac Sanayi Ticaret Ltd
Original Assignee
Rs Arastirma Egitim Danismanlik Llac Sanayi Ticaret Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rs Arastirma Egitim Danismanlik Llac Sanayi Ticaret Ltd filed Critical Rs Arastirma Egitim Danismanlik Llac Sanayi Ticaret Ltd
Priority to GB1611405.0A priority Critical patent/GB2551979A/en
Publication of GB201611405D0 publication Critical patent/GB201611405D0/en
Priority to IL263965A priority patent/IL263965B2/en
Priority to PCT/IB2017/053567 priority patent/WO2018002761A1/en
Priority to US16/314,328 priority patent/US20190321479A1/en
Priority to BR112019000029-1A priority patent/BR112019000029B1/pt
Priority to HRP20231642TT priority patent/HRP20231642T1/hr
Priority to EP23178285.5A priority patent/EP4260874A1/en
Priority to HUE17733906A priority patent/HUE064705T2/hu
Priority to JP2018569157A priority patent/JP6937329B2/ja
Priority to FIEP17733906.6T priority patent/FI3478323T3/fi
Priority to IL321408A priority patent/IL321408A/en
Priority to CN201780045704.2A priority patent/CN109475637A/zh
Priority to KR1020257017360A priority patent/KR20250084234A/ko
Priority to ES17733906T priority patent/ES2966774T3/es
Priority to EP17733906.6A priority patent/EP3478323B1/en
Priority to MX2019000277A priority patent/MX2019000277A/es
Priority to CA3029318A priority patent/CA3029318A1/en
Priority to PL17733906.6T priority patent/PL3478323T3/pl
Priority to KR1020197002227A priority patent/KR102539137B1/ko
Priority to EA201990142A priority patent/EA038984B1/ru
Priority to KR1020237007512A priority patent/KR20230035709A/ko
Priority to AU2017286869A priority patent/AU2017286869B2/en
Priority to DK17733906.6T priority patent/DK3478323T3/da
Priority to PT177339066T priority patent/PT3478323T/pt
Publication of GB2551979A publication Critical patent/GB2551979A/en
Priority to MX2024000877A priority patent/MX2024000877A/es
Priority to IL302564A priority patent/IL302564B2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
    • C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
    • C08F220/285—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing a polyether chain in the alcohol moiety
    • C08F220/286—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing a polyether chain in the alcohol moiety and containing polyethylene oxide in the alcohol moiety, e.g. methoxy polyethylene glycol (meth)acrylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F220/60—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing nitrogen in addition to the carbonamido nitrogen
    • C08F220/603—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing nitrogen in addition to the carbonamido nitrogen and containing oxygen in addition to the carbonamido oxygen and nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/10—Esters
    • C08F222/1006—Esters of polyhydric alcohols or polyhydric phenols
    • C08F222/106—Esters of polycondensation macromers
    • C08F222/1063—Esters of polycondensation macromers of alcohol terminated polyethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
GB1611405.0A 2016-06-30 2016-06-30 Cleavable polymer drug conjugates Withdrawn GB2551979A (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GB1611405.0A GB2551979A (en) 2016-06-30 2016-06-30 Cleavable polymer drug conjugates
PT177339066T PT3478323T (pt) 2016-06-30 2017-06-15 Conjugados de polímero-fármaco cliváveis
KR1020257017360A KR20250084234A (ko) 2016-06-30 2017-06-15 절단가능한 폴리머 약물 접합체
EP17733906.6A EP3478323B1 (en) 2016-06-30 2017-06-15 Cleavable polymer drug conjugates
US16/314,328 US20190321479A1 (en) 2016-06-30 2017-06-15 Cleavable polymer drug conjugates
BR112019000029-1A BR112019000029B1 (pt) 2016-06-30 2017-06-15 Conjugado polímero-fármaco, métodos para preparar o mesmo, composição farmacêutica que compreende o dito conjugado, bem como o uso do mesmo para o tratamento e/ou a profilaxia de câncer
HRP20231642TT HRP20231642T1 (hr) 2016-06-30 2017-06-15 Konjugati polimer-lijek koji se mogu cijepati
EP23178285.5A EP4260874A1 (en) 2016-06-30 2017-06-15 Cleavable polymer drug conjugates
HUE17733906A HUE064705T2 (hu) 2016-06-30 2017-06-15 Hasítható polimer-hatóanyag konjugátumok
JP2018569157A JP6937329B2 (ja) 2016-06-30 2017-06-15 切断可能なポリマー薬物コンジュゲート
FIEP17733906.6T FI3478323T3 (fi) 2016-06-30 2017-06-15 Lohkaistavissa olevia polymeeri-lääkekonjugaatteja
IL321408A IL321408A (en) 2016-06-30 2017-06-15 Cleavable polymer drug conjugates
CN201780045704.2A CN109475637A (zh) 2016-06-30 2017-06-15 可切割的聚合物药物偶联物
IL263965A IL263965B2 (en) 2016-06-30 2017-06-15 Cleavable drug polymer conjugates
ES17733906T ES2966774T3 (es) 2016-06-30 2017-06-15 Conjugados polímero-fármaco escindibles
PCT/IB2017/053567 WO2018002761A1 (en) 2016-06-30 2017-06-15 Cleavable polymer drug conjugates
MX2019000277A MX2019000277A (es) 2016-06-30 2017-06-15 Conjugados polimero-farmaco escindibles.
CA3029318A CA3029318A1 (en) 2016-06-30 2017-06-15 Cleavable polymer drug conjugates
PL17733906.6T PL3478323T3 (pl) 2016-06-30 2017-06-15 Rozszczepialne koniugaty polimer-lek
KR1020197002227A KR102539137B1 (ko) 2016-06-30 2017-06-15 절단가능한 폴리머 약물 접합체
EA201990142A EA038984B1 (ru) 2016-06-30 2017-06-15 Расщепляемые конъюгаты полимера и лекарственного средства
KR1020237007512A KR20230035709A (ko) 2016-06-30 2017-06-15 절단가능한 폴리머 약물 접합체
AU2017286869A AU2017286869B2 (en) 2016-06-30 2017-06-15 Cleavable polymer drug conjugates
DK17733906.6T DK3478323T3 (da) 2016-06-30 2017-06-15 Spaltbare polymer-lægemiddelkonjugater
MX2024000877A MX2024000877A (es) 2016-06-30 2019-01-07 Conjugados polimero-farmaco escindibles.
IL302564A IL302564B2 (en) 2016-06-30 2023-05-01 Cleavable drug polymer conjugates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1611405.0A GB2551979A (en) 2016-06-30 2016-06-30 Cleavable polymer drug conjugates

Publications (2)

Publication Number Publication Date
GB201611405D0 GB201611405D0 (en) 2016-08-17
GB2551979A true GB2551979A (en) 2018-01-10

Family

ID=56891421

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1611405.0A Withdrawn GB2551979A (en) 2016-06-30 2016-06-30 Cleavable polymer drug conjugates

Country Status (19)

Country Link
US (1) US20190321479A1 (enExample)
EP (2) EP4260874A1 (enExample)
JP (1) JP6937329B2 (enExample)
KR (3) KR20230035709A (enExample)
CN (1) CN109475637A (enExample)
AU (1) AU2017286869B2 (enExample)
CA (1) CA3029318A1 (enExample)
DK (1) DK3478323T3 (enExample)
EA (1) EA038984B1 (enExample)
ES (1) ES2966774T3 (enExample)
FI (1) FI3478323T3 (enExample)
GB (1) GB2551979A (enExample)
HR (1) HRP20231642T1 (enExample)
HU (1) HUE064705T2 (enExample)
IL (3) IL321408A (enExample)
MX (2) MX2019000277A (enExample)
PL (1) PL3478323T3 (enExample)
PT (1) PT3478323T (enExample)
WO (1) WO2018002761A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
GB2556055B (en) 2016-11-16 2022-03-23 Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret Ltd Sti Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
US12150996B2 (en) * 2017-11-17 2024-11-26 Centre National De La Recherche Scientifique Polymeric prodrugs and subcutaneous and/or intramuscular administration thereof
CN108752507A (zh) * 2018-05-12 2018-11-06 辽宁大学 一种酶敏感和氧化还原敏感双重响应型共聚物及其制备方法和应用
TR201911542A2 (tr) * 2019-07-30 2021-02-22 Bogazici Ueniversitesi Anti̇kor-poli̇mer konjugatlari
JP2022549680A (ja) * 2019-09-26 2022-11-28 スターファーマ ピーティーワイ エルティーディー 治療用デンドリマー
CN112608364B (zh) * 2020-12-09 2023-08-29 四川瀛瑞医药科技有限公司 一种果胶-阿霉素轭合物及其中间体的制备方法
CN115010913B (zh) * 2022-06-17 2023-05-26 广东工业大学 一种pH/还原双重响应聚合物胶束及其制备方法与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076771A2 (en) * 2006-12-15 2008-06-26 Abbott Cardiovascular Systems Inc. Coatings of acrylamide-based copolymers
WO2010042638A2 (en) * 2008-10-07 2010-04-15 Young Bok Lee Hpma - docetaxel or gemcitabine conjugates and uses therefore
WO2011047051A2 (en) * 2009-10-13 2011-04-21 Rexahn Pharmaceuticals, Inc. Polymeric systems for the delivery of anticancer agents
WO2012014003A1 (en) * 2010-07-28 2012-02-02 Corning Incorporated Pre-polymer preparations for cell culture coatings
CN105168230A (zh) * 2015-09-02 2015-12-23 上海市普陀区中心医院 一种具有内涵体逃逸功能的肿瘤靶向前药及其纳米制剂和制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
ATE317703T1 (de) 1997-06-12 2006-03-15 Innovata Plc Polymer-wirkstoff-konjugate zur behandlung von krebs
CN1308347C (zh) 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
CZ2005558A3 (cs) * 2005-09-05 2007-04-04 Zentiva, A. S. Zpusob prípravy polymerních konjugátu doxorubicinu s pH-rízeným uvolnováním léciva
CZ303072B6 (cs) * 2009-02-13 2012-03-21 Zentiva, K.S. Polymerní konjugáty paclitaxelu a docetaxelu s pH rízeným uvolnováním kancerostatika
WO2014152451A2 (en) * 2013-03-14 2014-09-25 University Of Rochester Compositions and methods for controlled localized delivery of bone forming therapeutic agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076771A2 (en) * 2006-12-15 2008-06-26 Abbott Cardiovascular Systems Inc. Coatings of acrylamide-based copolymers
WO2010042638A2 (en) * 2008-10-07 2010-04-15 Young Bok Lee Hpma - docetaxel or gemcitabine conjugates and uses therefore
WO2011047051A2 (en) * 2009-10-13 2011-04-21 Rexahn Pharmaceuticals, Inc. Polymeric systems for the delivery of anticancer agents
WO2012014003A1 (en) * 2010-07-28 2012-02-02 Corning Incorporated Pre-polymer preparations for cell culture coatings
CN105168230A (zh) * 2015-09-02 2015-12-23 上海市普陀区中心医院 一种具有内涵体逃逸功能的肿瘤靶向前药及其纳米制剂和制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Enzyme-cleavable polymeric micelles for the intracellular delivery of pro-apoptotic peptides", H.B. Kern et al, Molecular Pharmaceutics, just accepted manuscript, published 9th March 2017 *
WPI Abstract Accession No 2016-02214Y & CN 105168230A *

Also Published As

Publication number Publication date
DK3478323T3 (da) 2024-01-02
PT3478323T (pt) 2024-01-02
AU2017286869A1 (en) 2019-02-07
EP3478323A1 (en) 2019-05-08
IL263965B2 (en) 2023-10-01
KR20190022718A (ko) 2019-03-06
IL302564A (en) 2023-07-01
IL302564B2 (en) 2025-11-01
CA3029318A1 (en) 2018-01-04
IL263965B1 (en) 2023-06-01
HRP20231642T1 (hr) 2024-03-15
EP3478323B1 (en) 2023-09-27
KR20230035709A (ko) 2023-03-14
GB201611405D0 (en) 2016-08-17
MX2019000277A (es) 2019-05-27
IL263965A (en) 2019-01-31
JP2019527209A (ja) 2019-09-26
EA038984B1 (ru) 2021-11-18
WO2018002761A1 (en) 2018-01-04
CN109475637A (zh) 2019-03-15
BR112019000029A2 (pt) 2019-04-24
FI3478323T3 (fi) 2023-12-20
PL3478323T3 (pl) 2024-03-04
ES2966774T3 (es) 2024-04-24
EA201990142A1 (ru) 2019-06-28
AU2017286869B2 (en) 2022-05-05
KR102539137B1 (ko) 2023-06-01
MX2024000877A (es) 2024-02-09
IL321408A (en) 2025-08-01
US20190321479A1 (en) 2019-10-24
KR20250084234A (ko) 2025-06-10
EP4260874A1 (en) 2023-10-18
HUE064705T2 (hu) 2024-04-28
AU2017286869A8 (en) 2019-02-14
IL302564B1 (en) 2025-07-01
JP6937329B2 (ja) 2021-09-22

Similar Documents

Publication Publication Date Title
AU2017286869B2 (en) Cleavable polymer drug conjugates
AU2023248123B2 (en) Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
CN102686243B (zh) 用于抗癌剂递送的聚合物系统
CA2739757A1 (en) Hpma - docetaxel or gemcitabine conjugates and uses therefore
BR122024016269A2 (pt) Conjugado polímero-fármaco, métodos para preparar o mesmo, composição farmacêutica que compreende o dito conjugado, bem como uso do mesmo para tratamento e/ou profilaxia de câncer
BR112019000029B1 (pt) Conjugado polímero-fármaco, métodos para preparar o mesmo, composição farmacêutica que compreende o dito conjugado, bem como o uso do mesmo para o tratamento e/ou a profilaxia de câncer
EA044119B1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
BR112019009656B1 (pt) Conjugados polímero-fármaco, conjuntos poliméricos, composição farmacêutica compreendendo os mesmos, usos dos ditos conjugados e conjuntos para o tratamento e/ou profilaxia de câncer e métodos para a preparação do conjugado polímero-fármaco

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)